12 results on '"Roncero, C."'
Search Results
2. Trends in psychiatric hospitalization for alcohol and drugs in Castilla y León between 2005 and 2015.
- Author
-
Llanes-Álvarez C, Andrés-de Llano JM, Álvarez-Navares AI, Pastor-Hidalgo MT, Roncero C, and Franco-Martín MA
- Subjects
- Ethanol, Hospitalization, Humans, Spain, Tobacco Use, Alcohol Drinking trends, Illicit Drugs, Substance-Related Disorders epidemiology, Substance-Related Disorders therapy
- Abstract
It has been estimated that alcohol, tobacco, and illicit drugs were responsible for more than 10 million deaths worldwide in 2016, and there are many opportunities for improvement. Regarding innovative data analysis, advances have been made in the extraction of information from administrative databases for analytics purposes. We studied trends in hospitalization rates for alcohol and drug abuse over eleven years with Joinpoint Trend Analysis software. This is a descriptive study of cross-associations in 3,758 hospital admissions of patients admitted with a main diagnosis of alcohol and drug abuse or dependence in psychiatry units of public health centres of Castilla y León (Spain) between 2005 and 2015. Hospitalization trends for alcohol and drug related conditions declined over the eleven-year period. Separately, there was a statistically significant decrease in alcohol and cocaine related conditions, but a strong upward trend in cannabis related conditions between 2013 and 2015. Alcohol was the main cause of admission to psychiatric units with a diagnosis of addiction. In the 11 years researched, there was a progressive and constant reduction in admissions for substance use except for cannabis. The innovative statistical methodology has already proven to be useful for identifying trends and changes in different pathologies over time.
- Published
- 2022
- Full Text
- View/download PDF
3. A comparison between phase-III trials and a phase-IV study of nalmefene in alcohol use disorder patients. Is there a difference?
- Author
-
Barrio Giménez P, Ortega L, Guardia J, Roncero C, Yuguero L, and Gual A
- Subjects
- Adult, Alcoholism epidemiology, Behavior, Addictive epidemiology, Comorbidity, Female, Humans, Male, Mental Disorders epidemiology, Middle Aged, Naltrexone administration & dosage, Naltrexone therapeutic use, Narcotic Antagonists administration & dosage, Risk, Alcoholism complications, Alcoholism drug therapy, Naltrexone analogs & derivatives, Narcotic Antagonists therapeutic use
- Abstract
Concerns regarding the external validity of phase-III trials are common to many medical disciplines, with relevant discrepancies found between experimental and clinical samples in some diseases such as hypertension. The aim of this study was to compare the samples included in the pivotal, phase-III clinical trials of nalmefene with that of a recently conducted phase-IV trial. Baseline characteristics of the studies were compared through univariate analysis. Significant differences were found in the percentage of low-risk drinkers included. Differences were also found in the prescription and intake pattern of nalmefene, as well as in the rate of psychiatric and addictive comorbidities, which were much higher in the phase-IV study. These data suggest that in the field of alcohol use disorders there are also relevant differences between experimental and clinical samples, a fact that reinforces the need for phase-III trials to be balanced with observational, phase-IV trials.
- Published
- 2019
- Full Text
- View/download PDF
4. Harm reduction program use, psychopathology and medical severity in patients with methadone maintenance treatment.
- Author
-
Martínez-Luna NG, Rodríguez-Cintas L, Esojo A, Palma-Álvarez RF, Robles-Martínez M, Grau-López L, Perea M, and Roncero C
- Subjects
- Adult, Female, Humans, Male, Middle Aged, Severity of Illness Index, Harm Reduction, Methadone therapeutic use, Narcotics therapeutic use, Opiate Substitution Treatment, Opioid-Related Disorders drug therapy
- Abstract
Methadone maintenance programs (MMP) for opioid dependence treatment have been widely used due to their effective therapeutic outcomes. Harm reduction programs (HRP) are complementary programs for severe patients with high risk behaviors and when abstinence is not possible. This study aims to compare patients in MMP that use HRP (MMP-HRP) and patients in MMP who do not use HRP (MMP-NO HRP). The sample was composed of 143 patients (MMP-HRP = 42 vs. MMP-NO HRP = 101). An additional subanalysis was performed with patients under 45 years of age (n = 116; MMP-HRP = 38 vs. MMP-NO HRP = 78). All patients were assessed with an ad hoc socio-demographic questionnaire, EuropASI, SCID-I, and SCID-II. Results show that MMP-HRP patients were younger with more frequent use of intravenous drugs and with a high prevalence of Cluster B personality disorders. MMP-NO HRP patients had lower methadone doses compared to MMP-HRP patients and preferred to use drugs by smoked route more frequently. In the subanalysis of patients under 45, MMP-HRP patients were younger, had a higher prevalence of liver diseases, more intravenous drug use, greater severity on the drug use scale, less social and family support in the suescales of EUROP-ASI than compared to patients under 45 years in the group MMP-NO HRP. In conclusion, MMP-HRP patients are younger compared to MMP-NO HRP patients, they also receive higher doses of methadone and had more intravenous use. The above findings imply that the early onset of high risk drug use and long-term exposure to heroin have more severe outcomes such as higher comorbidities (e.g. infectious diseases, medical and psychiatric disorders), and consequently, these patients are a more vulnerable group with a worse prognosis.
- Published
- 2018
- Full Text
- View/download PDF
5. Chronic Hepatitis C and people with a history of injecting drugs in Spain: population assessment, challenges for effective treatment.
- Author
-
Roncero C, Vega P, Martinez-Raga J, and Torrens M
- Subjects
- Humans, Spain, Treatment Outcome, Hepatitis C, Chronic drug therapy, Substance Abuse, Intravenous epidemiology
- Abstract
Editorial.
- Published
- 2017
- Full Text
- View/download PDF
6. Management of opioid-dependent patients: comparison of the cost associated with use of buprenorphine/naloxone or methadone, and their interactions with concomitant treatments for infectious or psychiatric comorbidities.
- Author
-
Roncero C, Domínguez-Hernández R, Díaz T, Fernández JM, Forcada R, Martínez JM, Seijo P, Terán A, and Oyagüez I
- Subjects
- Drug Interactions, Humans, Analgesics, Opioid economics, Analgesics, Opioid therapeutic use, Buprenorphine economics, Buprenorphine therapeutic use, Health Care Costs, Infections complications, Infections drug therapy, Mental Disorders complications, Mental Disorders drug therapy, Methadone economics, Methadone therapeutic use, Naloxone economics, Naloxone therapeutic use, Narcotic Antagonists economics, Narcotic Antagonists therapeutic use, Opiate Substitution Treatment, Opioid-Related Disorders drug therapy, Opioid-Related Disorders economics
- Abstract
The objective was to estimate the annual interaction management cost of agonist opioid treatment (AOT) for opioid-dependent (OD) patients with buprenorphine-naloxone (Suboxone®) (B/N) or methadone associated with concomitant treatments for infectious (HIV) or psychiatric comorbidities. A costs analysis model was developed to calculate the associated cost of AOT and interaction management. The AOT cost included pharmaceutical costs, drug preparation, distribution and dispensing, based on intake regimen (healthcare center or take-home) and type and frequency of dispensing (healthcare center or pharmacy), and medical visits. The cost of methadone also included single-dose bottles, monthly costs of custody at pharmacy, urine toxicology drug screenings and nursing visits. Potential interactions between AOT and concomitant treatments (antivirals, antibacterials/antifungals, antipsychotics, anxiolytics, antidepressant and anticonvulsants), were identified to determine the additional use of healthcare resources for each interaction management. The annual cost per patient of AOT was €1,525.97 for B/N and €1,467.29 for methadone. The average annual cost per patient of interaction management was €257.07 (infectious comorbidities), €114.03 (psychiatric comorbidities) and €185.55 (double comorbidity) with methadone and €7.90 with B/N in psychiatric comorbidities. Total annual costs of B/N were €1,525.97, €1,533.87 and €1,533.87 compared to €1,724.35, €1,581.32 and €1,652.84 for methadone per patient with infectious, psychiatric or double comorbidity respectively.Compared to methadone, the total cost per patient with OD was lower with B/N (€47.45-€198.38 per year). This is due to the differences in interaction management costs associated with the concomitant treatment of infectious and/or psychiatric comorbidities.
- Published
- 2015
7. Motivational interviewing group at inpatient detoxification, its influence in maintaining abstinence and treatment retention after discharge.
- Author
-
Bachiller D, Grau-López L, Barral C, Daigre C, Alberich C, Rodríguez-Cintas L, Valero S, Casas M, and Roncero C
- Subjects
- Adult, Aged, Female, Hospitalization, Humans, Longitudinal Studies, Male, Middle Aged, Patient Compliance, Patient Discharge, Pilot Projects, Recurrence, Motivational Interviewing, Substance-Related Disorders therapy
- Abstract
The relapse rate after discharge from inpatient detoxification is high. The objective of this pilot study is to assess the sociodemographic, clinical and therapeutic factors associated with maintaining abstinence in patients who participated in a brief motivational interviewing group during admission for detoxification. A total of 46 patients, diagnosed substance dependent according to DSM -IV, and admitted to the Hospital Detoxification Unit, participated in a brief motivational interviewing group. Sociodemographic, clinical, motivation to change (University of Rhode Island Change Assessment, URICA) and satisfaction with the treatment group (Treatment Perceptions Questionnaire, CPT) data were collected. Abstinence and treatment retention two months after discharge were assessed by weekly telephone calls. A survival analysis was performed. Being male, having more cognitions of the maintenance stage of change at discharge, being satisfied with group therapy and therapist during hospitalization are associated with longer abstinence after discharge. The brief motivational interviewing group approach with patients admitted for detoxification is related to greater likelihood of maintaining abstinence and subsequent treatment retention.
- Published
- 2015
8. Attention deficit hyperactivity disorder and central nervous system depressants dependence. A review.
- Author
-
Daigre C, Terán A, García-Vicent V, and Roncero C
- Subjects
- Humans, Attention Deficit Disorder with Hyperactivity complications, Central Nervous System Depressants, Opioid-Related Disorders complications
- Abstract
The comorbidity between attention deficit hyperactivity disorder (ADHD) and substance use disorders is very common. A review of literature addressing prevalence, clinical features and treatment of the comorbidity between ADHD and CNS depressants was conducted. The prevalences found have a wide range (4.5% to 58%). ADHD has been associated with greater severity of addiction, early onset of consumption and addiction, more psychiatric comorbidity and more chronicity. In drug-dependent patients the diagnosis is a complex process because the frequent overlap of symptoms. The screening instruments should be used with caution. Drug therapy has shown efficacy in reducing ADHD symptoms, but there is no consensus regarding their influence on substance use. However, results should be interpreted cautiously, because the samples are small. Psychoeducational interventions are relevant, but treatment outcomes have not been described or studied systematically.
- Published
- 2013
9. [Risk factors for relapse in drug-dependent patients after hospital detoxification].
- Author
-
Grau-López L, Roncero C, Daigre C, Gonzalvo B, Bachiller D, Rodriguez-Cintas L, Egido Á, and Casas M
- Subjects
- Adult, Female, Follow-Up Studies, Hospitalization, Humans, Male, Multivariate Analysis, Prospective Studies, Recurrence, Risk Factors, Substance-Related Disorders therapy, Substance-Related Disorders epidemiology
- Abstract
This work describes the profile of patients with relapse after hospital detoxification at six months of outpatient follow-up. An observational and prospective study was carried out in patients with substance-dependence disorder who were in the Detoxification Unit of the Vall d'Hebron University Hospital (Barcelona) between June 2009 and October 2010. Demographic, clinical, diagnostic and therapeutic variables were assessed. The criterion for relapse was a return to use of the substance that had led to hospitalization, and relapse was assessed by means of anamnesis, breathalyzer and/or urine analysis. Study variables were compared between patients who relapsed and those who did not. Of the 165 patients included, 108 patients finished the study (75% males, age 37.7 ± 9.5 years). A total of 72.2% had relapsed at the 6-month follow-up. Profile of patients who relapsed was: hospitalized for heroin detoxification (91.7% vs 8.3%, p = .038), polyconsumers (71.4% vs 32%, p = .05), high substance use in the hours prior to admission as a "farewell" (61.5% vs 39.5%, p = .04), patients with comorbidity (44.9% vs 23.3%, p = .04) and patients with affective disorders (19.5% vs 3.2%, p = .005). Detoxification from opiates and use in the hours prior to admission were associated independently with relapse at 6 months. There is a high percentage of relapses after hospital detoxification. Patients most likely to relapse are those dependent on opiates and those with compulsive use immediately prior to hospitalization.
- Published
- 2012
10. [Smoking in affective psychosis: review about nicotine use in bipolar and schizoaffective disorders].
- Author
-
López-Ortiz C, Roncero C, Miquel L, and Casas M
- Subjects
- Affective Disorders, Psychotic epidemiology, Bipolar Disorder epidemiology, Humans, Psychotic Disorders epidemiology, Affective Disorders, Psychotic complications, Bipolar Disorder complications, Psychotic Disorders complications, Smoking epidemiology, Smoking therapy
- Abstract
Affective psychoses include those disorders with psychotic and affective symptoms described in the DSM-IV-TR. In these pathologies, the prevalence of nicotine dependence is very high. The objective here is to carry out a review of the relation between nicotine use and psychiatric disorders considered as affective psychoses at the epidemiological, clinical, prognostic and treatment levels. We review studies published in the PubMed database that include the keywords smoking, tobacco, nicotine and schizoaffective or bipolar disorder. Comorbidity of bipolar and schizoaffective disorder with nicotine consumption is 66-82.5 % and 67%, respectively. On the basis of this review it can be concluded that smoking results in poorer prognosis and greater clinical seriousness of bipolar and schizoaffective disorders. Use of other substances, psychiatric diagnosis, clinical seriousness and caffeine consumption are risk factors for nicotine use. The most effective treatment approach is pharmacological treatment in combination with psychological interventions. The first-line medication for tobacco detoxification and dishabituation are substitution therapy (transdermal patches, sprays, sublingual tablets, sucking pills or nicotine chewing gums), varenicline and bupropion. The medically indicated treatment for psychotic symptoms is atypical antipsychotics, due to their better tolerability profile and better results in smoking cessation.
- Published
- 2011
11. [Epidemiological and diagnostic axis I gender differences in dual diagnosis patients].
- Author
-
Miquel L, Roncero C, López-Ortiz C, and Casas M
- Subjects
- Diagnosis, Dual (Psychiatry), Female, Humans, Male, Sex Factors, Mental Disorders diagnosis, Mental Disorders epidemiology, Substance-Related Disorders diagnosis, Substance-Related Disorders epidemiology
- Abstract
Introduction: Dual diagnosis is the co-occurrence of a substance abuse disorder and a psychiatric condition. Gender has been found to be associated with differences in prevalence of mental disorders as well as outcome, prognosis and treatment-seeking., Material and Methods: Articles published in Medline, Web of Science and Journal Citation Reports up to December 2009 that examined gender, prevalence and clinical characteristics of dual-diagnosis patients aged over 18 were reviewed., Conclusions: The distribution of Axis I disorders by gender is similar for dually diagnosed patients and single-disorder patients. The prevalence of psychotic and bipolar disorders is higher in men, whereas anxiety and affective disorders are more prevalent in women. Dually diagnosed females with psychotic disorders do not show better prognosis than men. Finally, polydrug use among dual-diagnosis individuals is more prevalent in males.
- Published
- 2011
12. [Concomitant lithium and methadone treatment in a bipolar patient: a case report].
- Author
-
Roncero C, López-Ortiz C, Barral C, Sáez-Francàs N, Rovira M, and Casas M
- Subjects
- Drug Interactions, Drug Therapy, Combination, Female, Humans, Middle Aged, Antimanic Agents therapeutic use, Bipolar Disorder drug therapy, Lithium Compounds therapeutic use, Methadone therapeutic use, Narcotics therapeutic use
- Abstract
Dual diagnosis requires complex therapeutic approaches to adapt treatment to the dual nature of the problem. It is important to understand the drug effects and the drug interactions that may be observed during the integral treatment of these pathologies. Given the scarcity of data on the effects of lithium and methadone treatment, the aim of this clinical case report is to explain the interactions produced between methadone and lithium carbonate, in a female patient with medical multi-pathology, opioid-dependent and with comorbid bipolar disorder, who was treated with both drugs. The most common adverse effects for each drug are described. Drug interactions and temporal correspondence of the two drugs, as well as their dosages, are described through review of the retrospective chart and prospective follow-up of the patient. After one year of follow-up the patient had experienced no interactions in the concomitant lithium and methadone treatment. It should be noted that treatment of bipolar patients with dual diagnosis is complex, and should only be carried out by experts.
- Published
- 2009
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.